CriticalClass III antiarrhythmic×Non-selective beta blocker with class III antiarrhythmic activity
Updated · Methodology
Mechanism
Dronedarone and sotalol are both class III antiarrhythmics: they prolong the cardiac action potential and the QT interval (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA, and sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dronedarone has properties of all four antiarrhythmic classes, including class II non-competitive antagonism of adrenergic activity, and sotalol is a non-selective beta-blocker (EMA, AEMPS). The European dronedarone SmPC contraindicates dronedarone with drugs that can induce torsade de pointes, including class I and III antiarrhythmics, because of the potential risk of proarrhythmia. In clinical studies, bradycardia was more frequent when dronedarone was given with beta-blockers (EMA). The body does not metabolise sotalol, and 80–90% of the dose leaves the body unchanged in urine (AEMPS). The documents contain no data on dronedarone changing sotalol levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With dronedarone, prolongation of the heart-rate-corrected QT interval (QTc, Bazett) is very common and bradycardia is common (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Sotalol can cause torsade de pointes, usually after starting treatment or increasing the dose, and its incidence rises with the dose. In clinical trials, 13% of people taking sotalol had a heart rate below 50 beats per minute (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk of torsade de pointes is higher with a history of QT prolongation above 450 ms, a heart rate below 60 beats per minute, low potassium and magnesium, and other QT-prolonging drugs (AEMPS).
Management
The combination is contraindicated. The European dronedarone summary of product characteristics (SmPC) contraindicates dronedarone with class I and III antiarrhythmics and states that sotalol must be stopped before dronedarone is started (dronedarone SmPC, European Medicines Agency, EMA). The original Spanish sotalol SmPC contraindicates sotalol with class III antiarrhythmics and names dronedarone (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US labels also say to stop class I and III antiarrhythmics, including sotalol, before starting dronedarone, and to stop class I or III antiarrhythmics at least three half-lives before the first dose of sotalol (dronedarone and sotalol labels, US Food and Drug Administration, FDA). The European dronedarone SmPC gives no interval for switching from sotalol. The half-life of sotalol is 10–20 hours (AEMPS), and dronedarone and its metabolite are completely cleared from plasma 2 weeks after dronedarone is stopped (EMA). Do not stop sotalol abruptly, especially in ischaemic heart disease: reduce the dose gradually over 1–2 weeks with monitoring (AEMPS). Dronedarone is contraindicated with a heart rate below 50 beats per minute or a heart-rate-corrected QT interval (QTc, Bazett) of 500 ms or more. Correct potassium and magnesium deficiency before and during treatment. The SmPC recommends monitoring during treatment, including an electrocardiogram (ECG). Stop dronedarone if QTc reaches 500 ms or more (EMA). Start sotalol and increase its dose after an ECG with QTc measurement and an assessment of kidney function, electrolytes and concomitant medicines. The SmPC recommends doing this in a facility that can monitor heart rhythm (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Betapace / Betapace AF (sotalol hydrochloride) tablets – prescribing information (2024)– FDA label, Legacy Pharma USA, DailyMed setid a6a7702f-36c9-45db-b640-453dc324baee, version 2, 12/2024, sections 4, 5.1 and 7.1
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Sotapor (sotalol) (nº registro 62001), sección 4.3 (2022)– AEMPS, CIMA, nº registro 62001, revisión 11/2022, secciones 4.3, 4.4 y 4.5